The U.S. Food and Drug Administration has approved Oxecta, an tamper-resistant form of the top selling painkiller oxycodone.

Oxecta can be abused in a manner similar to other opioids and narcotics, Pfizer and Acura said in a released statement.

People who have severe asthma, upper-airway obstruction or chronic obstructive pulmonary disease (COPD) should not take Oxecta, according the companies news release.

The companies stated that some common adverse reactions include nausea, constipation, vomiting, headache, itchiness, insomnia, dizziness and lack of energy.